Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study-Reference-Cited by-同舟云学术

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

Published:2008-06-26 Issue:9 Volume:22 Page:1665-1679
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Appel I M,Kazemier K M,Boos J,Lanvers C,Huijmans J,Veerman A J P,van Wering E,den Boer M L,Pieters R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2008165.pdf

Reference54 articles.

1. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893–901.

2. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana–Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.

3. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336.

4. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T . Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 2001; 15: 1892–1897.

5. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R . [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97]. Klin Padiatr 1999; 211: 233–238.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. l‐Asparaginase Bio‐Betters: Insight Into Current Formulations, Optimization Strategies and Future Bioengineering Frontiers in Anti‐Cancer Drug Development;Advanced Therapeutics;2024-08-19

2. In Silico-Driven Engineering ofHalomonas elongataL-Asparaginase: Towards Enhanced Proteolytic Resistance in Lymphoblastic Leukemia;2024-06-08

3. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia;Pharmaceutical Research;2024-03-27

4. Desensitization using pegaspargase in the era of commercially available Erwinia: A single‐institution report on efficacy, cost, and resource utilization;Pediatric Blood & Cancer;2024-02-04

5. In Silico-Driven Engineering of Halomonas Elongata L-Asparaginase: Towards Enhanced Proteolytic Resistance in Lymphoblastic Leukemia;2024